Talent Lessons Learned From The Pharmaceutical Industry Through A Global Pandemic

In this article from the Armstrong Craven Review Volume 7, our experts explore how to scale talent when, as with any emerging technology, there is a tiny pool of talent. Brought about by the pandemic, there is now intense competition for niche talent specialising in Vaccines, as well-funded pharmaceutical firms seek to bring them on board to develop new mRNA drugs.

This article covers key topics:

  • “What can we do about the talent bottleneck”?

  • What acquisition lessons can we learn from the Pharmaceutical Industry’s rapid development?

  • Why HR leaders need a comprehensive workforce plan modelled around potential risks and opportunities

The success of mRNA vaccines is likely to attract developing talent. Therefore, firms must also think about how to engage and court the up-and-coming talent that will be ready in a few years. A proactive approach to talent is required as firms that invest in identifying, developing and engaging with future-ready talent will gain a competitive advantage when it is time to bring them on board. 

BioNTech’s CEO, Uğur Şahin, remarked: “You can't just switch over from producing vaccines instead of aspirin or cough syrup. The process requires years of expertise and the appropriate structural and technological equipment”.

Firms who will have the competitive advantage to win this talent war are those that are able to get insights into the talent landscape. The key to scaling talent is in preparation. Detailed talent insight will give your organisation the tools to confidently implement talent investment decisions.

Complete the form above to access your copy.